Search Immortality Topics:

Page 429«..1020..428429430431..440450..»


Category Archives: Stem Cell Therapy

Annabelle to undergo stem cell therapy

MANILA, Philippines Talent manager Annabelle Rama revealed that she will be undergoing stem cell therapy in September.

She confirmed this report to The Philippine Stars entertainment columnist Ricky Lo.

Rama said shes been suffering from several illnesses and that stem cell therapy may help make her feel better.

Im suffering from high-blood pressure, high-blood sugar and other ailments and from what I heard, after the therapy I would feel better. Lahat daw yon gagaling, she said.

Rama said her son Richard Gutierrez, who will be paying for the whole procedure, also urged her to have her back problem checked.

Richard wants me to have my scoliosis checked and my lumbar region which are giving me so much pain. So I will have two more injections for that, each costing an extra one thousand euros, she said.

Lo said in his article that the whole package, which will include nine injections, will cost around P1 million.

Meanwhile, although she earlier vented on Twitter her disappointment that her family is against her plan to run for Congress, it seems that her children have changed their mind about politics.

Rama said she is hoping that she will feel renewed after her upcoming stem cell therapy so she will be ready to file her certificate of candidacy as a Cebu congresswoman when she comes back.

Richard and my other children want me to be physically fit for the campaign, Rama said.

Read the rest here:
Annabelle to undergo stem cell therapy

Posted in Stem Cell Therapy | Comments Off on Annabelle to undergo stem cell therapy

News Coverage of CIRM Awards: Substantial but Not Extensive


The California stem cell agency today
enjoyed substantial, if sparse, news coverage of the

$151 million in research funding
approved by its board yesterday.
Both the San Francisco Chronicle and
The Sacramento Bee carried solid stories on the grant awards. In the
case of the Chronicle, the story included compelling photos of
patients who spoke during emotional, tear-filled presentations.
The stories represent a modest change
from the past, when media outlets all but ignored the agency's
awards.
The Bee's Richard Chang wrote,

“For Melissa Biliardi of Santa
Maria, the (CIRM board) vote symbolizes hope. Her son, James
Birdsall, 32, was diagnosed four years ago with Huntington's disease.
The degenerative brain disorder could prove fatal over the next 10 to
15 years. There is currently no cure or treatment, but with the
grant, UC Davis researchers hope to deliver an effective therapy in
four years.
"'This is the most hope we've ever
had for a cure or treatment,' Biliardi said.”

The Chronicle's Erin Allday wrote,

“California's stem cell funding
agency on Thursday approved nearly $100 million in grants for
research into heart disease, cancer and spinal cord injuries, and to
the cheers of dozens of patients and their supporters, it also
awarded money to rare but devastating diseases with no cure.”

The articles demonstrated the
effectiveness of patients and patient advocates in telling the CIRM
story. Reporters are always looking for a warm human dimension –
especially to enhance a dry, bare-bones science and government story.
Responding to a question from the
California Stem Cell Report, Kevin McCormack, spokesman for CIRM,
also mentioned radio news coverage in the San Francisco Bay Area. He
said the awards were covered in “two different stories on KCBS-AM
radio, one that ran several times yesterday and another that ran
several times today. KGO-AM radio also ran a story several tim, and,
of course, the best of all, today's KQED-FM Forum.”
The KQED show, which was also carried
nationally on Sirius radio, consisted of an hour-long look at CIRM,
with some calls from listeners. Guests on the show were CIRM
President, Alan Trounson, UC Davis stem cell researcher Jan Nolta and
yours truly, David Jensen.
Other stories appeared in the SanFrancisco Business Times and Genetic Engineering News. The Bee's
story appeared in the Modesto Bee as well.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cell Therapy, Stem Cells | Comments Off on News Coverage of CIRM Awards: Substantial but Not Extensive

Two More Disease Team Applications Sent Back for More Review


Directors of the California stem cell agency today referred two additional research applications for $37 million in disease team funding back to reviewers for further consideration.

Both were the subjects of appeals by researchers whose proposals were rejected by grant reviewers.

One was from Timothy Hoey of OncoMed Pharmaceuticals in Redwood City, who sought $20 million.  The other was from Henry Klassen of UC Irvine, who sought $17 million. (See here and here for their appeals.)

The  board began the day by directing staff to come back to the board in early September. But with the large number of grants to be reassessed, it was acknowledged some might not be acted on until the board's meeting in late October.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cell Therapy, Stem Cells | Comments Off on Two More Disease Team Applications Sent Back for More Review

Disease Team Round Hits $151 Million with Final Action


Directors of the California stem cell
agency approved an additional
$20 million disease team grant today before adjourning their
meeting. The grant brought the disease team round to a total of $151 million.

The award went to Judith  Shizuru 
of Stanford. Scientist Irv Weissman and Robert
Klein, former chairman of the stem cell agency, both spoke on behalf
of her
appeal of a negative decision by grant reviewers. 
At the suggestion of the current board
chairman, J.T. Thomas, the board placed conditions on the grant
would stipulate Stanford pick up certain unknown, additional costs if
necessary. 
Here is a link to the CIRM press release on today's action.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cell Therapy, Stem Cells | Comments Off on Disease Team Round Hits $151 Million with Final Action

Stem Cell Directors Approve $151 Million to Commercialize Stem Cell Research


Directors of the California stem cell
agency today approved $151 million in research awards aimed at
commercializing stem cell research and pushing therapies into
clinical treatment.


Patients and researchers cheered when the action was announced. 


The awards of up to $20 million each
were ratified by CIRM's governing board, which added two to the
six applications approved by reviewers. The original
six totalled $113 million. Directors budgeted $243 million
for today's round.


Five of the applications involving
appeals were sent back by the board for more review.
(See here, here and here.)
They will be considered again in early September or October.

The awards are the
second largest research round in CIRM's history,
surpassed only by an another, earlier $211 million “disease team”
round. The latest effort is aimed at bringing
proposed clinical trials to the FDA for approval or possibly starting
trials within four years. That deadline coincides roughly
with the date when CIRM is scheduled to run out of cash unless new
funding sources are developed.
CIRM is currently exploring seeking
private financing. It could also ask voters to approve another state
bond issue. (Bonds currently provide the only real source of cash for
CIRM.)  In either case, the agency needs strong, positive
results from its grantees to support a bid for continued funding.
Today's action came after nine out of
the 15  applicants who were rejected by reviewers appealed the
 negative decisions. Two of the appeals were successful at today's meeting. It is a
good bet that at least some of those referred for more review
will be ratified by the board in September. 
The appeals were based on a variety of
issues, ranging from technical science questions to inconsistencies
in CIRM's research approaches and mistakes by reviewers.
The outpouring
of appeals was the largest in CIRM history in terms of the
percentage of applicants seeking to overturn reviewer decisions.
The round also marked
another first in terms of the total initially approved by
reviewers. On occasion in the past, reviewers have not approved
enough awards to consume all the funds budgeted by the CIRM board.
But never before has the amount fallen so far short.
Most of the awards went to enterprises
connected to persons on 29-member CIRM governing board, continuing a
trend that has existed throughout CIRM's history. Board members with
conflicts, however, are not allowed to vote or participate in the
The full list of the winners and the
CIRM press release can be found here.

(Editor's note: This item was updated from an earlier version and the figures increased as the CIRM board added another grant and took additional action.)

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cell Therapy, Stem Cells | Comments Off on Stem Cell Directors Approve $151 Million to Commercialize Stem Cell Research

Harvard’s McMahon on His Way to USC


Andy McMahon
Harvard photo

The governing board of the California stem cell agency this afternoon approved a $5.7 million grant to lure a Harvard researcher to the University of Southern California in Los Angeles.

The scientist is Andrew McMahon, who serves on the executive committee of the Harvard Stem Cell Institute. CIRM officials said McMahon is ready to begin his work immediately at USC.

McMahon won stellar reviews from CIRM's grant reviewers who said he was an “exceptional scientist and one of the leading young developmental biologists.” Reviewers gave his proposal a score of 90 and, in summary, said,

“Major strengths include the candidate's exceptional productivity and contributions to the fields of mammalian embryology and kidney development, the significance and potential of the research program, the PI's proven leadership capabilities, and the outstanding institutional commitment.”

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cell Therapy, Stem Cells | Comments Off on Harvard’s McMahon on His Way to USC